信達生物(01801.HK)第一季總產品收入超過10億人民幣
信達生物(01801.HK)公布,今年第一季度,共取得總產品收入超過10億人民幣,較去年同期持續保持雙位數的快速增長,主要來自獲批商業化產品組合的持續放量增長。
季內,公司已取得七款產品獲批,包括:達伯舒(信迪利單抗注射液)、達攸同(貝伐珠單抗生物類似藥)、蘇立信(阿達木單抗生物類似藥)、達伯華(利妥昔單抗生物類似藥)、達伯坦(佩米替尼片)、耐立克(奧雷巴替尼)及和希冉擇(雷莫西尤單抗)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.